Who owns Biohaven Ltd. (BHVN)? Elite investor 13F holders

5 tracked elite investors reported holding Biohaven Ltd as of 2026-06-30, including D.E. Shaw, Rubric Capital, Sarissa Capital, Renaissance Technologies LLC, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawBIOHAVEN LTDSHARE2026-06-302026-08-14 00:00:0062350102.00 USD4190195.000000SharesaddOriginal filing
Rubric CapitalBIOHAVEN LTDSHARE2026-06-302026-08-14 00:00:0025615816.00 USD1721493.000000SharesbuyOriginal filing
Sarissa CapitalBIOHAVEN LTDSHARE2026-06-302026-08-14 00:00:008664803.00 USD582312.000000SharesaddOriginal filing
Renaissance Technologies LLCBIOHAVEN LTDSHARE2026-06-302026-08-13 00:00:002243190.00 USD150752.000000SharesreduceOriginal filing
Tudor InvestmentBIOHAVEN LTDSHARE2026-06-302026-08-14 00:00:001380462.00 USD92773.000000SharesaddOriginal filing
Pleasant Lake PartnersBIOHAVEN LTDSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown